JAMA Oncology Supports Effectiveness of Hologic's Genius™ 3D Mammography™ Exams

Hologic
share Share

Hologic Inc. (Nasdaq: HOLX) has announced that a new longitudinal study published online in advance of print in JAMA Oncology reports that women screened for breast cancer over multiple years using Hologic's Genius 3D MAMMOGRAPHY™ exams benefited from a significant drop in costly and stressful recalls.1

The findings published in JAMA Oncology provide longitudinal evidence that the benefits of 3D MAMMOGRAPHY™ exams – fewer women called back, more cancer cases found in recalled patients, and fewer cancers diagnosed between regular scheduled screenings – can be sustained and even improved over time with consecutive use. JAMA Oncology is a monthly peer-reviewed medical journal published by the American Medical Association. 

Emily F. Conant, MD, senior author, and her co-researchers analyzed screening mammography metrics for 23,958 women at the University of Pennsylvania Hospital over a four-year period. Differences in screening outcomes were assessed for women screened with standard digital mammography, women screened with 3D MAMMOGRAPHY™ exams, and women screened with 3D MAMMOGRAPHY™ exams over multiple years. The authors conclude that sustained, and even improved, performance is possible over time when 3D MAMMOGRAPHY™ exams are used in population-based screening.

"The new JAMA Oncology study is a significant addition to the already substantial body of research showing that Genius™ 3D MAMMOGRAPHY™ exams increase invasive cancer detection and reduce the number of women recalled for additional imaging," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions. "This new study demonstrates that the benefits of 3D MAMMOGRAPHY™ are sustainable, and further supports the importance and need for this life-saving technology."

Hologic's Genius™ 3D MAMMOGRAPHY™ exams have been available in the United States since February 2011. In 2015 an estimated 7.5 million women in the U.S. benefited from Genius™ 3D MAMMOGRAPHY™ exams.  Additional information, as well as a locator to find imaging sites offering the exams, can be found at http://mygenius3d.com/

Elizabeth S. McDonald, MD, PhD; Andrew Oustimov, MPH; Susan P. Weinstein, MD; Marie B. Synnestvedt, PhD; Mitchell Schnall, MD, PhD, and Emily F. Conant, MD. Effectiveness of Digital Breast Tomosynthesis Compared with Digital Mammography. JAMA Oncol. 2016;2(6):1-7. Doi:10:10.1001/jamoncol. 2015.5536.

Source & Image Credit : Hologic

Published on : Fri, 19 Feb 2016



Related Articles

Each year, more than 17,000 new breast cancer cases are reported in Poland, leading to over 5,600 deaths, many of which are primarily due... Read more

The CE-Marked Affirm™ Prone Biopsy System Provides Enhanced 2D/3D™ Biopsy Imaging and Faster, Easier Access to the Breast... Read more

Hologic, Inc. (Nasdaq: HOLX) has announced that the Company plans to release its financial results for the second quarter of fiscal... Read more

JAMA Oncology,Hologic,3D MAMMOGRAPHY Hologic Inc. (Nasdaq: HOLX) has announced that a new longitudinal study published online in advance of print in JAMA Oncology reports that women screened for breast cancer over multiple years using Hologic's Genius 3D MAMMOGRAPHY™ exams benefited from a s

No comment


Please login to leave a comment...

Highlighted Products